What is Aphea.Bio?
Founded in 2017, Aphea.Bio operates at the intersection of advanced microbiology and sustainable farming. The company specializes in developing novel, science-based agricultural inputs that address the dual challenges of food security and environmental stewardship. By focusing on biological alternatives to traditional chemical fertilizers and pesticides, Aphea.Bio provides farmers with tools to improve yield reliability while simultaneously lowering the ecological footprint of modern food production. Its market position is defined by a commitment to creating a more profitable and sustainable agricultural future, effectively bridging the gap between laboratory innovation and field-scale application.
How much funding has Aphea.Bio raised?
Aphea.Bio has raised a total of $105.5M across 3 funding rounds:
Series A
$10.9M
Series B
$16.8M
Series C
$77.8M
Series A (2017): $10.9M with participation from V-Bio Ventures, PMV, Vives Louvain Technology Fund, Qbic II, and Agri Investment Fund scrl
Series B (2020): $16.8M led by V-Bio Ventures, Vives, Astanor Ventures, PMV nv, and Agri Investment Fund scrl
Series C (2023): $77.8M supported by Bill & Melinda Gates Foundation, BNP Paribas, and Innovation Industries
Key Investors in Aphea.Bio
Bill & Melinda Gates Foundation
A global philanthropic organization dedicated to addressing extreme poverty and hunger by supporting innovative solutions that improve health and agricultural outcomes.
BNP Paribas
A leading international banking group that provides comprehensive financial services and supports large-scale infrastructure and sustainable innovation projects globally.
Innovation Industries
A specialized investment firm focused on backing high-growth technology companies that demonstrate significant potential for industrial and scientific disruption.
What's next for Aphea.Bio?
With the recent influx of capital, Aphea.Bio is poised to enter a pivotal stage of operational expansion. The strategic focus will likely shift toward the large-scale manufacturing and distribution of its biological products, alongside the continued refinement of its R&D platform. As the company scales, it will face the challenge of navigating complex regulatory environments and competitive global markets. However, the backing of major institutional investors and the proven efficacy of its technology suggest that Aphea.Bio is prepared to play a leading role in the ongoing transition toward regenerative and high-efficiency agricultural practices.
See full Aphea.Bio company page
